Trillium Therapeutics Inc.
TSX : TR
OTCQX : SCTPF

Trillium Therapeutics Inc.

June 13, 2014 10:00 ET

Trillium Therapeutics Receives Prestigious National Award

TORONTO, ONTARIO--(Marketwired - June 13, 2014) - Trillium Therapeutics Inc. ("TTI") (TSX:TR)(OTCQX:SCTPF), an immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has been awarded BIOTECanada's 2014 Gold Leaf Award as Early Stage Health Company of the Year.

"We are honored to receive this coveted national award," remarked Trillium's Chairman, Dr. Calvin Stiller. "The company had a remarkable year in 2013, culminating in an unprecedented capital raise from premier healthcare funds. This was made possible because of the substantial progress we made in advancing our innovative CD47 checkpoint inhibitor program towards the clinic. It is gratifying to see these accomplishments recognized by the industry."

"Every single member of the Trillium team has worked very hard to achieve our goals and we all feel rightfully proud of this award from BIOTECanada and our peers," added Dr. Niclas Stiernholm, President and CEO. "With the outstanding team that we are fortunate to have assembled, we are optimistic that the future of our company is bright."

About Trillium Therapeutics:

Trillium Therapeutics Inc. is an immuno-oncology company developing innovative therapies for the treatment of cancer. The Company has two premier preclinical programs, SIRPaFc and a CD200 monoclonal antibody (mAb), which target two key immunoregulatory pathways that tumor cells exploit to evade the host immune system. SIRPaFc is an antibody-like fusion protein that blocks the activity of CD47, a molecule that is upregulated on tumor cells in acute myeloid leukemia (AML) and numerous other malignancies. The CD200 mAb is a fully human monoclonal antibody that blocks the activity of CD200, an immunosuppressive molecule that is overexpressed by many hematopoietic and solid tumors. TTI's clinical stage programs include tigecycline, which is being evaluated in a multi-centre Phase I study in patients with AML and TTI-1612, which has been tested in a 28-patient Phase I trial in interstitial cystitis ("IC") patients. For more information, visit: www.trilliumtherapeutics.com

Caution Regarding Forward-Looking Information:

This press release may contain forward-looking statements, which reflect TTI's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include changing market conditions; the successful and timely completion of pre-clinical and clinical studies; the establishment of corporate alliances; the impact of competitive products and pricing; new product development risks; uncertainties related to the regulatory approval process or the ability to obtain drug product in sufficient quantity or at standards acceptable to health regulatory authorities to complete clinical trials or to meet commercial demand; and other risks detailed from time to time in TTI's ongoing quarterly and annual reporting. Except as required by applicable securities laws, TTI undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.

Contact Information